Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Journal of the National Cancer Institute
|
April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12
Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Blood
|
June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12
John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
American Journal of Hematology
|
November 23, 2017
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
Roland B Walter, Laura C Michaelis, Megan Othus, et al.
Vaccine
|
June 29, 2024
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies
Sita Bhella, Allison M Wilkin, Katrina Hueniken, et al.
British Journal of Haematology
|
October 10, 2025
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies
Abi Vijenthira, Sita Bhella, Katrina Hueniken, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 2, 2021
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia
Matthew C Cheung, Nicole Mittmann, Carolyn Owen, et al.
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
British Journal of Haematology
|
September 13, 2024
A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma
John Kuruvilla, Christopher Rushton, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12
Michael Crump, John Kuruvilla, Stephen Couban, et al.
NEJM Evidence
|
June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma
Angie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Journal of the National Cancer Institute
|
April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12
Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Blood
|
June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12
John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
American Journal of Hematology
|
November 23, 2017
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
Roland B Walter, Laura C Michaelis, Megan Othus, et al.
Vaccine
|
June 29, 2024
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies
Sita Bhella, Allison M Wilkin, Katrina Hueniken, et al.
British Journal of Haematology
|
October 10, 2025
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies
Abi Vijenthira, Sita Bhella, Katrina Hueniken, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 2, 2021
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia
Matthew C Cheung, Nicole Mittmann, Carolyn Owen, et al.
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
British Journal of Haematology
|
September 13, 2024
A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma
John Kuruvilla, Christopher Rushton, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12
Michael Crump, John Kuruvilla, Stephen Couban, et al.
NEJM Evidence
|
June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma
Angie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Page
of 6